Literature DB >> 10075013

Signalling of Bruton's tyrosine kinase, Btk.

A J Mohamed1, B F Nore, B Christensson, C I Smith.   

Abstract

Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation. It belongs to the Tec family of PTKs containing several domains that are characteristic of signalling molecules. In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinaemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of immunoglobulins. In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype. BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling molecules resulting in a physiological response such as B-cell proliferation and antibody production. The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several laboratories. This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochemical signals within the cell that eventually lead to nuclear responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075013     DOI: 10.1046/j.1365-3083.1999.00504.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  15 in total

1.  Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases: a case study involving PECAM-1.

Authors:  Benjamin E Tourdot; Michelle K Brenner; Kathleen C Keough; Trudy Holyst; Peter J Newman; Debra K Newman
Journal:  Biochemistry       Date:  2013-04-03       Impact factor: 3.162

2.  Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells.

Authors:  Irene Guendel; Sergey Iordanskiy; Gavin C Sampey; Rachel Van Duyne; Valerie Calvert; Emanuel Petricoin; Mohammed Saifuddin; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  J Neurovirol       Date:  2015-02-12       Impact factor: 2.643

3.  Palmitoylation of the Alternative Amino Terminus of the BTK-C Isoform Controls Subcellular Distribution and Signaling.

Authors:  Mostafa Kokabee; Xianhui Wang; Elena Voorand; Eden Alin; Leila Kokabee; Faiza Khan; Sophia Desrosiers; Douglas S Conklin
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

4.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

5.  Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells.

Authors:  Shruti Sharma; Gregory Orlowski; Wenxia Song
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 6.  Targeting B cells for the treatment of rheumatoid arthritis.

Authors:  Thomas J Oligino; Stacie A Dalrymple
Journal:  Arthritis Res Ther       Date:  2003-10-02       Impact factor: 5.156

7.  A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells.

Authors:  M G Tomlinson; D B Woods; M McMahon; M I Wahl; O N Witte; T Kurosaki; J B Bolen; J A Johnston
Journal:  BMC Immunol       Date:  2001-06-08       Impact factor: 3.615

8.  Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.

Authors:  Minako Ito; Takashi Shichita; Masahiro Okada; Ritsuko Komine; Yoshiko Noguchi; Akihiko Yoshimura; Rimpei Morita
Journal:  Nat Commun       Date:  2015-06-10       Impact factor: 14.919

9.  Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.

Authors:  Steven D Schutt; Jianing Fu; Hung Nguyen; David Bastian; Jessica Heinrichs; Yongxia Wu; Chen Liu; Daniel G McDonald; Joseph Pidala; Xue-Zhong Yu
Journal:  PLoS One       Date:  2015-09-08       Impact factor: 3.240

10.  Bruton's tyrosine kinase and protein kinase C µ are required for TLR7/9-induced IKKα and IRF-1 activation and interferon-β production in conventional dendritic cells.

Authors:  Yan-Feng Li; Koon-Guan Lee; Xijun Ou; Kong-Peng Lam
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.